SKYRIZI Market Expands to Multiple Autoimmune Diseases
DelveInsight’s latest report forecasts significant market growth for AbbVie’s SKYRIZI, driven by expanded approvals and strong efficacy in multiple autoimmune conditions.
A new market analysis by DelveInsight, published in March 2026, projects substantial growth for AbbVie’s SKYRIZI through 2034, highlighting its expanding role in treating various autoimmune diseases.
The drug has demonstrated remarkable sales performance, with global revenue estimated at approximately $11.7 billion for 2024, marking a significant 51% year-over-year increase. Initially approved for plaque psoriasis, SKYRIZI’s indications have broadened to include psoriatic arthritis and inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, significantly increasing its addressable patient population.
SKYRIZI targets the p19 subunit of interleukin-23 (IL-23), a key cytokine in autoimmune and inflammatory pathways. Clinical studies have reported high rates of skin clearance (PASI 90/100) in psoriasis patients and strong endoscopic and clinical remission in Crohn’s disease. The drug is positioned as a successor to older biologics like Humira, which has faced significant biosimilar erosion.
The report further emphasizes SKYRIZI’s strategic importance within AbbVie's immunology franchise. Combined sales of SKYRIZI and Rinvoq are projected to exceed $31 billion annually by 2027. Favorable factors include its subcutaneous administration and less frequent dosing schedule, enhancing patient convenience compared to older treatments.
The analysis covers SKYRIZI’s current performance and future market potential in key regions including the United States, Japan, EU4 countries (Germany, France, Italy, Spain), and the United Kingdom. It includes competitive landscape, risk analysis, and emerging treatment options.